Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome
Есипов А. В., Иволгин А. Ф., Хритинин Д. Ф., Катенко С. В., Казаков С. П., Каракозов А. Г., Калягин И. Е., Левченко О. Б., Молодова А. И.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 119, Вып. 9, С. 46-51
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.17116/jnevro201911909146
Аннотация:
Objective. To analyze the efficacy of cytoflavin in the complex treatment of sleep disorders in asthenic syndrome. Material and methods. One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied. The patients were divided into three groups depending on the type of therapy: the first group received intravenous infusions of cytoflavin for 10 days; the second group, in addition to cytoflavin, received per os melatonin (3 mg or 5 mg) at bedtime; the third group in addition to cytoflavin received per os zopiclone (7.5 mg) at bedtime. Results. On the 14th day of the study, a decrease in severity or complete relief of asthenia manifestations (according to the SHAS scale) and, accordingly, improvement or normalization of sleep in 97[%] of patients was found. At the same time, during polysom-nographic study, the data obtained are characteristic for improving the quality of sleep phases mainly in the first and second groups of patients and, to a
Ключевые слова:
Asthenia; Asthenic syndrome; Chronic fatigue syndrome; Cytoflavin; Insomnia; Melatonin; Sleep disturbance; Zopiclone
cytoflavin; melatonin; multivitamin; unclassified drug; zopiclone; antioxidant; cytoflavin; flavine mononucleotide; inosine diphosphate; melatonin; nicotinamide; succinic acid derivative; add on therapy; anxiety neurosis; Article; bedtime dosage; disease severity; drug dose comparison; drug efficacy; human; major clinical study; polysomnography; sleep disorder; sleep quality; treatment response; asthenia; clinical trial; drug combination; oral drug administration; syndrome; treatment outcome; Administration, Oral; Antioxidants; Asthenia; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Melatonin; Niacinamide; Sleep Wake Disorders; Succinates; Syndrome; Treatment Outcome
Язык текста: Русский
ISSN: 2309-4729
Есипов А. В.
Иволгин А. Ф.
Хритинин Д. Ф. Дмитрий Федорович 1936-
Катенко С. В. Сергей Владимирович 1964-
Казаков С. П.
Каракозов А. Г.
Калягин И. Е.
Левченко О. Б.
Молодова А. И.
Esipov A. V.
Ivolgin A. F.
Khritinin D. F. Dmitrij Fedorovich 1936-
Katenko S. V. Sergej Vladimirovich 1964-
Kazakov S. P.
Karakozov A. G.
Kalyagin I. E.
Levchenko O. B.
Molodova A. I.
Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 119, Вып. 9 С. 46-51
2019
Статья
Asthenia Asthenic syndrome Chronic fatigue syndrome Cytoflavin Insomnia Melatonin Sleep disturbance Zopiclone
cytoflavin melatonin multivitamin unclassified drug zopiclone antioxidant cytoflavin flavine mononucleotide inosine diphosphate melatonin nicotinamide succinic acid derivative add on therapy anxiety neurosis Article bedtime dosage disease severity drug dose comparison drug efficacy human major clinical study polysomnography sleep disorder sleep quality treatment response asthenia clinical trial drug combination oral drug administration syndrome treatment outcome Administration, Oral Antioxidants Asthenia Drug Combinations Flavin Mononucleotide Humans Inosine Diphosphate Melatonin Niacinamide Sleep Wake Disorders Succinates Syndrome Treatment Outcome
Objective. To analyze the efficacy of cytoflavin in the complex treatment of sleep disorders in asthenic syndrome. Material and methods. One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied. The patients were divided into three groups depending on the type of therapy: the first group received intravenous infusions of cytoflavin for 10 days; the second group, in addition to cytoflavin, received per os melatonin (3 mg or 5 mg) at bedtime; the third group in addition to cytoflavin received per os zopiclone (7.5 mg) at bedtime. Results. On the 14th day of the study, a decrease in severity or complete relief of asthenia manifestations (according to the SHAS scale) and, accordingly, improvement or normalization of sleep in 97[%] of patients was found. At the same time, during polysom-nographic study, the data obtained are characteristic for improving the quality of sleep phases mainly in the first and second groups of patients and, to a